Williams Syndrome Prevalence: Global Estimates and Diagnostic Considerations

Williams syndrome (WS) prevalence is estimated at 1 in 7,500 to 1 in 20,000 live births (~5–13 per 100,000). This translates to ~10,000–30,000 individuals in the U.S. and ~350,000–1,000,000 worldwide.

Factors Affecting Estimates

• Ascertainment bias: Clinical diagnosis misses mild/atypical cases.
• Genetic testing access: FISH (ELN deletion) or microarray confirms; not universally available.
• Population differences: Founder effects, consanguinity may alter local rates.
• Age distribution: Improved survival → increasing prevalence over time.

Diagnostic Criteria

• Characteristic facies (periorbital fullness, stellate iris, wide mouth)
• Cardiovascular: Supravalvular aortic stenosis (SVAS), peripheral pulmonary stenosis
• Neurodevelopmental: Mild-moderate ID, unique cognitive profile (strong language/social, weak visuospatial)
• Hypercalcemia (infancy), connective tissue abnormalities, endocrine issues
• Confirmatory: 7q11.23 microdeletion (1.5–1.8 Mb, 26–28 genes) by FISH or CMA.

Clinical Implications

• Multisystem care: Cardiology, genetics, developmental pediatrics, nephrology, endocrine.
• Anesthesia risk: Coronary artery anomalies, difficult airway.
• Family screening: Parents usually negative (de novo); recurrence risk <1% (gonadal mosaicism rare).

WS is rare but recognizable. Early diagnosis enables proactive cardiovascular surveillance and developmental support.